Intra-articular duration of Durolane™ after single injection into the rabbit knee

Cartilage

Volumn 2, Issue 4, 2011, Pages 384-388

  Edsman, Katarina ^a   Hjelm, Roland ^a   Lärkner, Helena ^a   Nord, Lars I ^a   Karlsson, Anders ^a   Wiebensjö, Åsa ^a   Höglund, A Urban ^b   Kenne, Anne Helander ^a   Näsström, Jacques ^a,c  

^a Q Med AB   (Sweden)

^b Visionar Preclinical AB   (Sweden)

^c PledPharma AB   (Sweden)

Author keywords

Duration; Durolane ; Hyaluronic acid; Intra articular; Osteoarthritis

Indexed keywords

EID: 84857131434     PISSN: 19476035     EISSN: 19476043     Source Type: Journal    
DOI: 10.1177/1947603511400184     Document Type: Article

References (19)

1. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. 1993;39(Suppl): 3-9.
2. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid: I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum. 1967;10:357-376.
3. Mazzucco D, Scott R, Spector M. Composition of joint fluid in patients undergoing total knee replacement and revision arthroplasty: correlation with flow properties. Biomaterials. 2004;25:4433-4445.
4. Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology. 2007;44:59-74.
5. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32:10-37.
6. Punzi L. The complexity of the mechanisms of action of hyaluronan in joint diseases. Clin Exp Rheumatol. 2001;19:242-246.
7. Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev. 2006;58:226-242.
8. Brown TJ, Laurent UB, Fraser JR. Turnover of hyaluronan in the synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol. 1991;76:125-134.
9. Lindehayn HH, Heilmann HH, Niederhausen HUW, Pohlenz K. Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. Eur J Chem Clin Biochem. 1997;35:355-363.
10. Larsen NE, Dursema H, Skrabut EM. Clearance kinetics of a single injection crosslinked hylan-based viscosupplement in a rabbit model [abstract]. Osteoarthritis and Cartilage. 2007;15:C64.
11. Ågerup B, Berg P, Åkermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19:23-30.
12. Lindqvist U, Tolmachev V, Kairemo K, Åström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41: 603-613.
13. De la Peña E, Sala S, Rovira JC, Schmidt R, Belmonte C. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain. 2002;99:501-508.
14. Gotoh S, Onaya J-I, Abe M, Miyazaki K, Hamai A, Horie K, Tokuyasu K. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52:817-822.
15. Gomis A, Pawlak M, Balasz EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004;50:314-326.
16. Gomis A, Miralles A, Schmidt RF, Belmonte C. Nociceptive nerve activity in an experimental model of knee joint osteoarthritis of the guinea pig: effect of intra-articular hyaluronan application. Pain. 2007;130:126-136.
17. Åkermark C, Berg P, Björkman A, Malm P. Non-animal stabilized hyaluronic acid in the treatment of osteoarthritis of the knee: A tolerability study. Clin Drug Invest. 2002;22:157-166.
18. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a metaanalysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86:538-545.
19. Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;1:1-76.